Lovenox Injection
Product Images NDC 55154-4028

25 FDA label images from Cardinal Health 107, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Lovenox (NDC 55154-4028). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure A (5017a927 2a24 4f27 89f9 27c805bf7d59 01)

Figure A (5017a927 2a24 4f27 89f9 27c805bf7d59 01)
An instructional illustration showing two hands connecting or disconnecting two parts of a syringe or injection device. The hands hold the syringe components facing each other with a bidirectional arrow between them indicating connection or separation.*
FDA Label Image

Figure B (5017a927 2a24 4f27 89f9 27c805bf7d59 02)

Figure B (5017a927 2a24 4f27 89f9 27c805bf7d59 02)
An instructional diagram showing a hand administering a subcutaneous injection into the skin with a syringe. The image includes an arrow indicating the direction of injection, demonstrating the proper technique for injecting the medication below the skin surface.*
FDA Label Image

Figure C (5017a927 2a24 4f27 89f9 27c805bf7d59 03)

Figure C (5017a927 2a24 4f27 89f9 27c805bf7d59 03)
An instructional illustration showing a hand holding a syringe with an injection needle poised for subcutaneous administration, indicated by an arrow pointing toward the skin. This image likely demonstrates the proper technique for injecting Lovenox (enoxaparin sodium) subcutaneously.*
FDA Label Image

Figure D (5017a927 2a24 4f27 89f9 27c805bf7d59 04)

Figure D (5017a927 2a24 4f27 89f9 27c805bf7d59 04)
An instructional illustration depicting a hand holding a syringe with the needle pointing upward. The thumb is positioned to press the plunger, indicating the process of preparing or administering an injection.*
FDA Label Image

Figure E (5017a927 2a24 4f27 89f9 27c805bf7d59 05)

Figure E (5017a927 2a24 4f27 89f9 27c805bf7d59 05)
An instructional illustration demonstrating the correct disposal of a used injection needle into a designated sharps disposal container marked with a biohazard symbol. A hand is shown dropping a capped needle into the container's opening, emphasizing safe handling for subcutaneous injections.*
FDA Label Image

Chemical Structure (5017a927 2a24 4f27 89f9 27c805bf7d59 06)

Chemical Structure (5017a927 2a24 4f27 89f9 27c805bf7d59 06)
Chemical structure of enoxaparin sodium, the active ingredient in Lovenox injection 40 mg/.4mL by Cardinal Health 107, LLC. The structure depicts repeating saccharide units typical of low molecular weight heparin.*
FDA Label Image

Chemical Structure (5017a927 2a24 4f27 89f9 27c805bf7d59 07)

Chemical Structure (5017a927 2a24 4f27 89f9 27c805bf7d59 07)
Chemical structure diagram of the active ingredient enoxaparin sodium, showing its molecular components and bonds as commonly depicted in pharmaceutical labeling.*
FDA Label Image

Figure 1 (5017a927 2a24 4f27 89f9 27c805bf7d59 08)

Figure 1 (5017a927 2a24 4f27 89f9 27c805bf7d59 08)
A forest plot chart depicting the relative risk of outcomes comparing unfractionated heparin (UFH) and enoxaparin (Enox) across various patient subgroups. The chart lists subgroups by sex, age, infarct location, diabetes status, prior myocardial infarction, fibrinolytic agent type, time to treatment, and PCI status in 30 days, showing the number of patients, percentage outcomes for UFH and enoxaparin, and the reduction in risk, with a visual scale indicating whether enoxaparin or UFH is favored.*
FDA Label Image

Figure 2 (5017a927 2a24 4f27 89f9 27c805bf7d59 09)

Figure 2 (5017a927 2a24 4f27 89f9 27c805bf7d59 09)
A Kaplan-Meier hazard distribution function graph depicting the time to death or myocardial reinfarction over 30 days for patients treated with Enoxaparin (Lovenox) versus Unfractionated Heparin (UFH). The graph shows overlapping risk curves, number at risk counts for each day interval, and a log-rank test p-value indicating statistical comparison between treatments. An inset graph illustrates the hazard with extended follow-up to 1 year.*
FDA Label Image

Figure (5017a927 2a24 4f27 89f9 27c805bf7d59 10)

Figure (5017a927 2a24 4f27 89f9 27c805bf7d59 10)
Instructional diagram showing the Lovenox injection syringe before and after use. The 'Before Use' side labels the plunger rod, needle, and needle cap. The 'After Use' side highlights the plunger rod and the protective sleeve covering the needle.*
FDA Label Image

Figure A (5017a927 2a24 4f27 89f9 27c805bf7d59 11)

Figure A (5017a927 2a24 4f27 89f9 27c805bf7d59 11)
An instructional illustration showing the components included with the Lovenox prefilled syringe injection package. It depicts the Lovenox syringe along with a cotton ball or gauze, an alcohol wipe, a small adhesive bandage, and a sharps disposal container for safe syringe disposal.*
FDA Label Image

Figure B (5017a927 2a24 4f27 89f9 27c805bf7d59 12)

Figure B (5017a927 2a24 4f27 89f9 27c805bf7d59 12)
An instructional illustration showing a person removing the backing from an adhesive strip on a Lovenox prefilled syringe, demonstrating preparation for subcutaneous injection.*
FDA Label Image

Figure C (5017a927 2a24 4f27 89f9 27c805bf7d59 13)

Figure C (5017a927 2a24 4f27 89f9 27c805bf7d59 13)
A black and white instructional illustration showing a syringe with a needle attached and a plunger. The syringe body includes a label area indicating the location for the expiration date. The nozzle and needle cover are shown on the left side.*
FDA Label Image

Figure D (5017a927 2a24 4f27 89f9 27c805bf7d59 14)

Figure D (5017a927 2a24 4f27 89f9 27c805bf7d59 14)
An instructional illustration of a syringe labeled with the presence of clear liquid inside the barrel, showing components including the plunger and needle in a side view.*
FDA Label Image

Figure E (5017a927 2a24 4f27 89f9 27c805bf7d59 15)

Figure E (5017a927 2a24 4f27 89f9 27c805bf7d59 15)
An instructional diagram illustrating abdominal injection sites. The image shows the front torso with two gray shaded rectangular areas indicating where subcutaneous injections can be administered, avoiding the central abdominal area around the navel.*
FDA Label Image

Figure F (5017a927 2a24 4f27 89f9 27c805bf7d59 16)

Figure F (5017a927 2a24 4f27 89f9 27c805bf7d59 16)
An instructional illustration showing a hand holding a cloth or wipe and cleaning or preparing an area of skin on a person's abdomen, likely indicating preparation for a subcutaneous injection.*
FDA Label Image

Figure G (5017a927 2a24 4f27 89f9 27c805bf7d59 17)

Figure G (5017a927 2a24 4f27 89f9 27c805bf7d59 17)
An instructional illustration showing two hands preparing a Lovenox injection. One hand holds the syringe, and the other removes the needle cover by pulling it straight off, indicated by double-headed arrows.*
FDA Label Image

Figure H (5017a927 2a24 4f27 89f9 27c805bf7d59 18)

Figure H (5017a927 2a24 4f27 89f9 27c805bf7d59 18)
An instructional illustration showing a hand holding a syringe with the thumb on the plunger, indicating the motion of pressing down. The syringe is marked with measurement lines, and an arrow points downward with accompanying text "Set your dose" guiding dose adjustment for injection.*
FDA Label Image

Figure I (5017a927 2a24 4f27 89f9 27c805bf7d59 19)

Figure I (5017a927 2a24 4f27 89f9 27c805bf7d59 19)
An instructional illustration showing a person’s hand pulling up the waistband of their pants, demonstrating preparation for a subcutaneous injection, likely related to the use of Lovenox (enoxaparin sodium) injection.*
FDA Label Image

Figure J (5017a927 2a24 4f27 89f9 27c805bf7d59 20)

Figure J (5017a927 2a24 4f27 89f9 27c805bf7d59 20)
An instructional illustration showing the subcutaneous injection technique for Lovenox (enoxaparin sodium) injection. The drawing depicts a hand holding a syringe at a 90-degree angle to the skin surface, with the needle inserted into the abdominal area. A thumb is shown slightly pinching the skin at the injection site, and an arrow indicates the direction of injection.*
FDA Label Image

Figure K (5017a927 2a24 4f27 89f9 27c805bf7d59 21)

Figure K (5017a927 2a24 4f27 89f9 27c805bf7d59 21)
An instructional diagram showing a hand administering a subcutaneous injection with a syringe into the abdominal area. The illustration highlights proper angle and positioning for injection, with an arrow indicating the direction of the injection.*
FDA Label Image

Figure L (5017a927 2a24 4f27 89f9 27c805bf7d59 22)

Figure L (5017a927 2a24 4f27 89f9 27c805bf7d59 22)
An instructional illustration showing the administration of Lovenox (enoxaparin sodium) subcutaneous injection. The image depicts a hand holding a syringe at an angle to the abdomen, indicating the injection site and direction for subcutaneous injection.*
FDA Label Image

Figure M (5017a927 2a24 4f27 89f9 27c805bf7d59 23)

Figure M (5017a927 2a24 4f27 89f9 27c805bf7d59 23)
An instructional illustration showing a hand holding a syringe with a protective sleeve. The image indicates a 'click' action, likely demonstrating how to activate or assemble the protective sleeve on the syringe for a Lovenox injection.*
FDA Label Image

Figure N (5017a927 2a24 4f27 89f9 27c805bf7d59 24)

Figure N (5017a927 2a24 4f27 89f9 27c805bf7d59 24)
An instructional illustration showing a hand holding a Lovenox syringe above a sharps disposal container. Labeled parts include the Lovenox syringe and the needle cap. The diagram depicts safe disposal of the needle cap into the sharps disposal container.*
FDA Label Image

40mg/0.4ml Bag Label (51658faf 4b60 4c8a A1e6 6bd612300651 00)

40mg/0.4ml Bag Label (51658faf 4b60 4c8a A1e6 6bd612300651 00)
Label for Lovenox 40 mg/0.4 mL injection, enoxaparin sodium, in a package of 5 single-dose syringes with automatic safety device for subcutaneous use. Manufactured by sanofi-aventis U.S. LLC, distributed by Cardinal Health.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.